406 related articles for article (PubMed ID: 34590937)
1. Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer.
Rijavec E; Genova C; Biello F; Rossi G; Indini A; Grossi F
Expert Rev Respir Med; 2021 Nov; 15(11):1427-1435. PubMed ID: 34590937
[TBL] [Abstract][Full Text] [Related]
2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
4. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
[No Abstract] [Full Text] [Related]
6. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life.
Korde R; Veluswamy R; Allaire JC; Barnes G
Curr Med Res Opin; 2022 Aug; 38(8):1361-1368. PubMed ID: 35575164
[TBL] [Abstract][Full Text] [Related]
7. Small cell lung cancer: a slightly less orphan disease after immunotherapy.
Remon J; Aldea M; Besse B; Planchard D; Reck M; Giaccone G; Soria JC
Ann Oncol; 2021 Jun; 32(6):698-709. PubMed ID: 33737119
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
9. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
10. Role of Immune Checkpoint Inhibitors in Small Cell Lung Cancer.
Cooper MR; Alrajhi AM; Durand CR
Am J Ther; 2018; 25(3):e349-e356. PubMed ID: 29722737
[TBL] [Abstract][Full Text] [Related]
11. The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.
Zhang S; Bi M
Ann Palliat Med; 2020 Nov; 9(6):4081-4088. PubMed ID: 33302668
[TBL] [Abstract][Full Text] [Related]
12. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
13. The role of immunotherapy in small cell lung cancer.
Calles A; Aguado G; Sandoval C; Álvarez R
Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective.
Walia HK; Sharma P; Singh N; Sharma S
Curr Treat Options Oncol; 2022 Feb; 23(2):268-294. PubMed ID: 35226309
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Ando K; Manabe R; Kishino Y; Kusumoto S; Yamaoka T; Tanaka A; Ohmori T; Ohnishi T; Sagara H
Curr Oncol; 2021 Feb; 28(2):1094-1113. PubMed ID: 33673470
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Liu X; Xing H; Zhang H; Liu H; Chen J
Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
[TBL] [Abstract][Full Text] [Related]
17. Evolving role of immunotherapy in small cell lung cancer.
Barrows ED; Blackburn MJ; Liu SV
Semin Cancer Biol; 2022 Nov; 86(Pt 3):868-874. PubMed ID: 35192928
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer.
Schlick B; Shields MD; Marin-Acevedo JA; Patel I; Pellini B
Curr Treat Options Oncol; 2022 Aug; 23(8):1104-1120. PubMed ID: 35716328
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
